Players submitted to 1,734 drug tests during the first quarter of the 2018 season, according to the Tennis Anti-Doping Program's quarterly report.
The report, which covers January through March of 2018, shows men submitted to 1,032 drug tests, while women were tested 732 times during the quarter.
Watch: Djokovic Fends off Coric
The Tennis Anti-Doping Program's 2018 first-quarter testing totals are here:
|
2018 First Quarter |
Total Samples |
Men |
Women |
|
In-Competition Urine Test |
941 |
612 |
329 |
|
In-Competition Blood Test |
20 |
10 |
10 |
|
In-Competition ABP Test |
48 |
48 |
0 |
|
Out-Of-Competition Urine Test |
253 |
125 |
128 |
|
Out-Of-Competition Blood Test |
226 |
113 |
113 |
|
Out-Of-Competition ABP Test |
246 |
124 |
122 |
|
Totals |
1,734 |
1,032 |
732 |
Notes: the statistics in the above tables do not include samples collected by National Anti-Doping Organisations (NADOs); ABP refers to blood samples collected under the Athlete Biological Passport program.
The TADP reported 22 Therapeutic Use Exemption applications were reviewed by the TADP TUE Committee in the first quarter of 2018. All TUE applications are now made through the TADP online TUE Portal.
Of the 22 applications, 19 were granted, and three were denied.
The TADP announced it's awaiting a decision from the Court of Arbitration for Sport in the appeal by the Italian National Anti-Doping Organization against the decision of the Independent Tribunal, which suspended Sara Errani for two months last year.
The former French Open finalist tested positive for trace amounts of Letrozole, classified as a hormone and metabolic modulator, served a two-month suspension and returned to tennis last October.
NADO Italia—which operates independently from the Italian Olympic Committee—filed an appeal with the Court of Arbitration for Sport seeking a longer sentence for Errani.
Photo credit: Mark Peterson/Corleve